Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 29/11/2020
SIETES contiene 93175 citas

 
 
 1 a 12 de 12 
Presentar resultados
Seleccionar todas
1. Cita con resumen
Connolly SJ, Milling Jr TJ, Eikelboom JW, Gibson CM, Curnutte JT, Gold A, Bronson MD, Lu G, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen AT, Beyer-Westendorf J, Albadalejo P, López-Sendon J, Goodman S, Leeds J, Wiens BL, Siegal DM, Zotova E, Meeks B, Nakamya J, Lim WT, Crowther M, for the ANNEXA-4 Investigators. Andexanet alfa for acute major bleeding associated with factor Xa inhibotors. N Engl J Med 2016;375:1131-41. [Ref.ID 100767]
2. Cita con resumen
Anderson DR, Dunbar MJ, Bohm ER, Belzile E, Kahn SR, Zukor D, Fisher W, Gofton W, Gross P, Pelet S, Crowther M, MacDonald S, Kim P, Pleasance S, Davis N, Andreou P, Wells P, Kovacs M, Rodger MA, Ramsay T, Carrier M, Vendittoli P-A. Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial. Ann Intern Med 2013;158:800-6. [Ref.ID 95589]
3. Cita con resumen
Dentall F, Riva N, Crowther M, Turpie AGG, Lip LYH, Ageno W. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation 2012;126:2381-91. [Ref.ID 93149]
4. Cita con resumen
Douketis J, Cook D, Meade M, Guyatt G, Geerts W, Skrobik Y, Albert M, Granton J, Hébert P, Pagliarello G, Marshall J, Fowler R, Freitag A, Rabbat C, Anderson D, Zytaruk N, Heels-Ansdell D, Crowther M, for the Canadian Critical Care Trials Group. Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin. Arch Intern Med 2008;168:1805-12. [Ref.ID 84093]
5.Tiene citas relacionadas
Cook D, Crowther M. Targeting anemia with erythropoietin during critical illness. N Engl J Med 2007;357:1037-9. [Ref.ID 80959]
7. Cita con resumen
Dentali F, Douketis JD, Woods K, Thabane L, Foster G, Holbrook A, Crowther M. Does celecoxib potentiate the anticoagulant effect of warfarin? A randomized, double-blind, controlled trial. Ann Pharmacother 2006;40:1241-7. [Ref.ID 77889]
8. Cita con resumen
Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, Wells PS. Systematic overview of warfarin and its drugs and food interactions. Arch Intern Med 2005;165:1095-106. [Ref.ID 73955]
9.
Nagge J, Crowther M, Hirsh J. Is impaired renal function a contraindication to the use of low-molecular-weight heparin?. Arch Intern Med 2002;162:2605-9. [Ref.ID 64396]
10.Tiene citas relacionadas
Crowther M, Gent M, Ginsberg J, Hirsh J. Vitamin K in anticoagulation therapy. Authors' reply. Lancet 2001;357:638. [Ref.ID 55352]
11.
Ginsberg JS, Wells PS, Kearon C, Anderson D, Crowther M, Weitz JI, Bormanis J, Brill-Edwards P, Turpie AG, MacKinnon B, Gent M, Hirsh J. Sensitivity and specificity of a rapid whole-blood assay for D-dimer in the diagnosis of pulmonary embolism. Ann Intern Med 1998;129:1006-11. [Ref.ID 42159]
12.
Harrison L, Johnston M, Massicotte MP, Crowther M, Moffat K, Hirsh J. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med 1997;126:133-6. [Ref.ID 31761]
Seleccionar todas
 
 1 a 12 de 12